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Substantial interassay variability (up to 20%) has been described for vancomycin immunoassays in adults, but the impact of neonatal
matrix is difficult to quantify because of blood volume constraints in neonates. However, we provide circumstantial evidence for
a similar extent of variability. Using the same vancomycin dosing regimens and confirming similarity in clinical characteristics,
vancomycin trough concentrations measured by PETINIA (2011-2012, 𝑛 = 400) were 20% lower and the mean difference was
1.93mg/L compared to COBAS (2012–2014, 𝑛 = 352) measurements. The impact of vancomycin immunoassays in neonatal matrix
was hereby suggested, supporting a switch to more advanced techniques (LC-MS/MS).
1. Introduction
Vancomycin, a glycopeptide antibiotic, is commonly used
in neonatal intensive care units (NICUs) for the treatment
of late onset sepsis and catheter-related infections [1]. In
adults, a ratio of the 24-hour area under the curve (AUC
0–24)
divided by the minimum inhibitory concentration (MIC) for
a given pathogen≥ 400 is considered to be the optimal predic-
tor of vancomycin efficacy for invasive methicillin-resistant
staphylococci (MRSA) respiratory infections. Vancomycin
serum concentrations are widely used as a surrogate marker
for AUC, aiming to achieve target trough concentrations
between 10 and 15mg/L during intermittent intravenous
administration [2].
Large interindividual variability in vancomycin phar-
macokinetics (PK) within the neonatal population is well-
known and is only in part explained by covariates such as
weight, age, or serum creatinine [3, 4]. Since therapeutic
drug monitoring (TDM) is clinically useful for drugs that
have a known relationship between measured bodily fluid
concentration and therapeutic effect, neonates with their
rapid developmental changes in pharmacokinetic parameters
will benefit from vancomycin TDM [5]. However, even if
TDM is implemented, the immunoassays currently used to
quantify vancomycin concentrations may differ because of
differences in matrix. Cross-validation of different published
PKmodels on vancomycin in neonates from different NICUs
failed [6]. Clinicians do not take into account that routine
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vancomycin quantification by commercial immunoassays
can indeed show substantial differences, and this is an
important clinical argument in support of a switch towards
LC-MS/MS methodologies [7–10].
While this phenomenon is obviously not limited to
neonatal matrix, the relevance may be population specific
because of differences in plasma composition (e.g., concen-
tration of albumin, immunoglobulins like IgA, and bilirubin)
[7, 8]. Current recommendations do not take into account
that routine plasma vancomycin quantification by commer-
cial immunoassays can show substantial between-method
differences. Next to standardization issues, immunoassays
can also lack specificity. Cross-reacting substances such as
vancomycin degradation products have been described to
interfere with some immunoassays [7–10].
Unfortunately, there are no data on the interassay dif-
ferences in neonatal matrix, likely due to blood volume
constraints. Since the blood samples are of very limited
quantity in neonates, it is not feasible to analyze different
between-assay differences in a paired study design as applied
in adult samples [7–9]. In an attempt to provide circum-
stantial evidence, we explored the impact of between-assay
differences on the variability in vancomycin serum trough
levelsmeasured in neonates treated in a single neonatal inten-
sive care unit (NICU) following a switch in immunoassay
(PETINIA to COBAS).
2. Design and Methods
2.1. Study Population, Clinical Data Collection, and Ethics.
Vancomycin trough concentrations measured in neonates
and young infants treated with intravenous vancomycin,
mainly for (suspected) late onset sepsis (>72 hours after
birth), in the NICU of the University Hospitals Leuven,
Belgium, between June 2011 and December 2014, were con-
sidered for inclusion in this retrospective study. Our patient
population consisted of preterm and term neonates, who
needed specialized care related to infections and prematurity.
Clinical characteristics at birth (birth weight [BW] in grams;
gestational age [GA] in weeks) and characteristics at the
moment of TDM (postmenstrual age [PMA] in weeks, post-
natal age [PNA] in days, weight at inclusion [WT] in grams,
serum creatinine (mg/dL), serum albumin (g/L), and serum
trough vancomycin concentration (mg/L)) were extracted
from the patient files. Results were excluded if data regarding
vancomycin prescription could not be obtained or in case of
an administration or sampling time error.The ethics board of
our hospital approved the study protocol.
2.2. Vancomycin Indication, Administration, TDM Collection,
and TDM Assays. Vancomycin (Vancocin, Elly Lilly, Brus-
sels, Belgium) combined with amikacin is used as standard
therapy for (suspected) late onset sepsis. Administration
occurs as an intravenous infusion over 60 minutes. The
vancomycin dosing regimen was based on PMA and serum
creatinine, irrespective of the vancomycin assay used [4]. As
part of routine clinical care trough samples for TDM were
collected at the end of the dosing interval, inmost cases 24–72
hours after treatment was initiated. Subsequent trough TDM
samples during the same course were collected based on the
decision of the attending physician. All samples during the
first vancomycin treatment course are included.
During the study period, two different vancomycin
immunoassays were applied consecutively. The vancomycin
serum trough concentrations were measured either by
a particle-enhanced turbidimetric inhibition immunoassay
method (Siemens Dimension; Dade Behring, Deerfield, Illi-
nois, PETINIA) or by an enzyme multiplied immunoas-
say technique (Cobas c702; Roche Diagnostics, Germany,
COBAS). In November 2012, the assay was changed from
PETINIA to COBAS throughout the entire hospital for
logistic, nonclinical reasons. The hospital laboratory has
a quality system that conforms to ISO15189. This implies
that clinical interchangeability of results is verified when
changing from one assay to another. To avoid censoring
of concentrations below the lower limit of quantification
(2mg/L), these concentrations were replaced by a lower
limit of quantification/2 (1mg/L) [11]. Throughout this study
interval, an enzymatic technique (Cobas c702 module) was
used to quantify serum creatinine concentrations, so issues
on Jaffe versus enzymatic creatinine assays do not apply
[12].
2.3. Data Analysis and Statistics. The data were analyzed by
Student’s 𝑡-test and Mann-Whitney 𝑈 test, as appropriate.
General linear modelling was performed to assess significant
differences between both groups, when adjusting for con-
founding factors. Since vancomycin serum concentrations
had a small deviation of distribution, these were transformed
using logarithmic transformation to obtain a normal distri-
bution. Data were analyzed in SPSS 20.0 (IBM corp.) and a 𝑝
value < 0.05 was considered statistically significant.
3. Results and Discussion
Our dataset comprised 313 patients with 752 vancomycin
trough TDM observations: 400 observations were assayed
with PETINIA and 352 with COBAS. Both cohorts had
comparable clinical characteristics and only differences for
serum albumin concentration were documented (Table 1).
We observed a significant difference between the
vancomycin trough concentrations using two different
immunoassays: PETINIA versus COBAS (𝐹 = 7.695;
𝑝 = 0.006, Figure 1). When adjusting for serum albumin
concentration and creatinine levels as critical covariates, the
difference in vancomycin concentration between cohorts
remained statistically significant (𝐹 = 4.567, 𝑝 = 0.033;
𝐹 = 4.302; 𝑝 = 0.038, resp.). According to these results, it
was shown that the vancomycin assay used was a significant
predictor of vancomycin serum concentration. Overall,
immunoassays PETINIA and COBAS yielded significantly
different vancomycin trough concentrations when adjusting
for covariates and the mean difference was 1.93mg/L. The
vancomycin serum trough concentrations measured by
PETINIA were 20% lower than those measured by COBAS
(Figure 1).
BioMed Research International 3
Table 1: Clinical characteristics of studied patients. Data are
provided by mean and standard deviation (SD).
Mean SD 𝑝 value
Gestational age (weeks)
PETINIA 31.91 5.17 0.635
COBAS 31.71 5.27
Birth weight (g)
PETINIA 1,779.48 991.96 0.182
COBAS 1,906.91 1,143.24
Weight at inclusion (g)
PETINIA 2,066.77 1,101.14 0.233
COBAS 2,220.59 1,288.11
Postmenstrual age (weeks)
PETINIA 34.77 5.98 0.766
COBAS 34.61 6.00
Postnatal age (days)
PETINIA 20.98 22.31 0.951
COBAS 22.13 23.38
Creatinine (mg/dL)
PETINIA 0.47 0.19 0.052
COBAS 0.52 0.24
Albumin (g/dL)
PETINIA 31.13 5.09
<0.001
COBAS 29.42 4.71
∗
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Figure 1: Vancomycin serum trough concentrations (mg/L) deter-
mined by two different immunoassays: PETINIA versus COBAS,
presented as box plots (Mann-Whitney 𝑈 test, 𝑝 < 0.05).
Vancomycin dosing strategies in neonates are mostly
based on postmenstrual and postnatal age, and they also
take into account the developmental changes in volume of
distribution and renal function as themost important covari-
ates influencing vancomycin clearance [2]. However, the
clinical significance of different analytical methods for serum
vancomycin concentration was only recently suggested in
neonates [6]. Between-assay studies in neonatal matrix are
hampered by the blood volume needed to perform multiple
between-assay studies, but we here provided circumstantial
evidence of the relevance and the impact.
This provides further evidence that dosage individual-
ization should not only consider clinical characteristics but
also be tailored to the method of vancomycin quantification
in neonates [6, 9]. We hereby speculate that this reflects the
fact that immunoglobulinM (IgM) or IgA affects vancomycin
concentrationmeasured by PETINIA [10].This might at least
in part explain between-assay differences in the neonatal
plasma matrix. Importantly, the relevance goes beyond our
single institution, as illustrated by Zhao et al.: the transfer-
ability of published models of vancomycin pharmacokinetics
to different clinical settings in part related to the use of
conversion factors to “correct” for differences in vancomycin
immune assays used [6].
The impact of vancomycin immunoassays in neonatal
matrix was hereby suggested, providing additional support
to switch to more advanced techniques (LC-MS/MS) to
avoid both thematrix related differences between immunoas-
says and to lower the blood volume needed to quantify
vancomycin in neonatal samples. Until then, clinicians
taking care for neonates should consider the impact of
immunoassays on vancomycin levels and targets. Similar,
researchers should consider including neonatal samples in
their assay comparison and assay development. Obviously
and because of the limitations (sample volume) and ethical
constrains in neonates, such studies should first be done
using samples for adult patients. Matrix effects (ion sup-
pression/enhancement) should hereby be considered, since
this is a well-observed phenomenon in analyses of biological
matrices by high-performance liquid chromatography-mass
spectrometry (LC-MS) [13]. This should be followed by
subsequent hypothesis testing, validation, or confirmation in
neonatal matrix. Pooling of neonatal samples is hereby one of
the approaches to further reduce this burden.
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